Pure Global AI
NCT05941169Not yet recruiting

Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy

A Prospective Study of Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy vs Primary Tumour in Place
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)ClinicalTrials.govprocedure
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
Cytoreductive Nephrectomy
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2023
End date
Apr 01, 2031
Enrollment
750 participants
Primary outcome

Overall Survival

Summary

The benefit of deferred Cytoreductive Nephrectomy (CN) has to be re-assessed in the context
 of IO +IO and IO + TKI systemic treatment. Given the benefit of CN in the setting of first
 generation immunotherapy, it is conceivable that both trials underestimated the benefit of
 CN, in absence of immunotherapy.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05941169
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05941169 through Pure Global AI's free database. This phase not specified trial is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 750 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.